Skip to main content

CORRECTION article

Front. Allergy, 10 January 2023
Sec. Asthma
Volume 3 - 2022 | https://doi.org/10.3389/falgy.2022.1119941
This article is part of the Research Topic Criteria to Be Considered in the Selection of Biological Agents Used in Severe Asthma View all 5 articles

Corrigendum: Uncontrolled severe T2 asthma: Which biological to choose? A biomarker-based approach

This article is a correction to:

  1. Uncontrolled severe T2 asthma: Which biological to choose? A biomarker-based approach

    1. Read original article
\r\nAntolín Lpez-ViaAntolín López-Viña1Rocio M. Diaz Campos Rocio M. Diaz Campos2*Andrea Trisan AlonsoAndrea Trisan Alonso1Carlos Melero Moreno\r\nCarlos Melero Moreno3
  • 1Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
  • 2Hospital Universitario 12 de Octubre, Madrid, Spain
  • 3Fundación Investigación Biomédica Hospital 12 de Octubre, Madrid, Spain

A Corrigendum on

Uncontrolled severe T2 asthma: Which biological to choose? A biomarker-based approach

By López-Viña A, Díaz Campos RM, Trisan Alonso A and Melero Moreno C. (2022) Front. Allergy 3:1007593. doi:10.3389/falgy.2022.1007593

Error in Figure/Table

In the published article, there was an error in Figure 1 as published. Many words in Figure 1 appeared underlined. The corrected Figure 1 and its caption appear below.

FIGURE 1
www.frontiersin.org

Figure 1. Algorithm to choose a monoclonal antibody.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: T2 severe asthma, monoclonal antibodies, biomarkers, exacerbations, systemic corticosteroids

Citation: López-Viña A, Diaz Campos RM, Trisan Alonso A and Melero Moreno C (2023) Corrigendum: Uncontrolled severe T2 asthma: Which biological to choose? A biomarker-based approach. Front. Allergy 3:1119941. doi: 10.3389/falgy.2022.1119941

Received: 9 December 2022; Accepted: 15 December 2022;
Published: 10 January 2023.

Approved by: Frontiers in Allergy Editorial Office, Frontiers Media SA, Switzerland

© 2023 López-Viña, Díaz Campos, Trisan Alonso and Melero Moreno. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Rocio M. Diaz Campos rociomdc80@gmail.com

Specialty Section: This article was submitted to Asthma, a section of the journal Frontiers in Allergy

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.